{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:23:27Z","timestamp":1789917807004,"version":"4.0.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.tcm.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T18:52:41Z","timestamp":1338922361000},"page":"97-104","source":"Crossref","is-referenced-by-count":55,"title":["PTPN11-Associated Mutations in the Heart: Has LEOPARD Changed Its RASpots?"],"prefix":"10.1016","volume":"21","author":[{"given":"Jessica","family":"Lauriol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Kontaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2012.03.006_bib1","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/MCB.23.21.7875-7886.2003","article-title":"Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling","volume":"23","author":"Agazie","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib2","first-page":"808","article-title":"Rapamycin and CCI-779","volume":"86","author":"Alexandre","year":"1999","journal-title":"Bull Cancer"},{"key":"10.1016\/j.tcm.2012.03.006_bib3","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1073\/pnas.0810053106","article-title":"Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation","volume":"106","author":"Araki","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tcm.2012.03.006_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm1084","article-title":"Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation","volume":"10","author":"Araki","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2012.03.006_bib5","doi-asserted-by":"crossref","first-page":"41677","DOI":"10.1074\/jbc.M306461200","article-title":"Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors","volume":"278","author":"Araki","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib6","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1073\/pnas.91.15.7335","article-title":"Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor \u03b2 to Ras","volume":"91","author":"Bennett","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tcm.2012.03.006_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/01.RES.81.2.176","article-title":"Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: Evidence for involvement of p70 S6 kinase","volume":"81","author":"Boluyt","year":"1997","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2012.03.006_bib8","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1093\/emboj\/19.23.6341","article-title":"The MEK1-ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice","volume":"19","author":"Bueno","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.tcm.2012.03.006_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/504394","article-title":"Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype","volume":"79","author":"Carta","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature09005","article-title":"Patient-specific induced pluripotent stem-cell\u2013derived models of LEOPARD syndrome","volume":"465","author":"Carvajal-Vergara","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tcm.2012.03.006_bib11","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1172\/JCI43910","article-title":"Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation","volume":"120","author":"Chen","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2012.03.006_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.497","article-title":"A restricted spectrum of NRAS mutations causes Noonan syndrome","volume":"42","author":"Cirstea","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.425","article-title":"Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair","volume":"41","author":"Cordeddu","year":"2009","journal-title":"Nat Genet"},{"issue":"Suppl 3","key":"10.1016\/j.tcm.2012.03.006_bib14","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1053\/j.seminoncol.2009.10.010","article-title":"Evaluating temsirolimus activity in multiple tumors: A review of clinical trials","volume":"36","author":"Dancey","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.tcm.2012.03.006_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/prot.22984","article-title":"Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase","volume":"79","author":"Darian","year":"2011","journal-title":"Proteins"},{"key":"10.1016\/j.tcm.2012.03.006_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ejhg.2008.256","article-title":"Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations","volume":"17","author":"Dentici","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.yjmcc.2011.03.001","article-title":"Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes","volume":"51","author":"Dhandapany","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/341528","article-title":"Grouping of multiple-lentigines\/LEOPARD and Noonan syndromes on the PTPN11 gene","volume":"71","author":"Digilio","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib19","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/MCB.00646-09","article-title":"Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase\/AKT\/glycogen synthase kinase 3beta signaling","volume":"30","author":"Edouard","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/excr.1999.4668","article-title":"SHP-2 tyrosine phosphatase: Signaling one cell or many","volume":"253","author":"Feng","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.tcm.2012.03.006_bib21","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1128\/MCB.16.12.6887","article-title":"A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion","volume":"16","author":"Fujioka","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.hjh.0000239304.01496.83","article-title":"Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis","volume":"24","author":"Gao","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.tcm.2012.03.006_bib23","first-page":"110","article-title":"The Leopard (multiple lentigines) syndrome revisited","volume":"7","author":"Gorlin","year":"1971","journal-title":"Birth Defects Orig Artic Ser"},{"key":"10.1016\/j.tcm.2012.03.006_bib24","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1074\/jbc.M312498200","article-title":"Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty","volume":"279","author":"Hanafusa","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib25","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.febslet.2006.03.088","article-title":"Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1","volume":"580","author":"Hanna","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.tcm.2012.03.006_bib26","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tcm.2012.03.006_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.tcm.2012.03.006_bib28","doi-asserted-by":"crossref","first-page":"H1531","DOI":"10.1152\/ajpheart.00216.2011","article-title":"LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt\/GSK-3\u03b2\/\u03b2-catenin signaling","volume":"301","author":"Ishida","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib29","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1371\/journal.pgen.0030225","article-title":"Shp2 knockdown and Noonan\/LEOPARD mutant Shp2-induced gastrulation defects","volume":"3","author":"Jopling","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib30","doi-asserted-by":"crossref","first-page":"30984","DOI":"10.1074\/jbc.M504699200","article-title":"Diverse biochemical properties of Shp2 mutants","volume":"280","author":"Keilhack","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib31","doi-asserted-by":"crossref","first-page":"22208","DOI":"10.1074\/jbc.270.38.22208","article-title":"Identification of a putative Syp substrate, the PDGF\u03b2 receptor","volume":"270","author":"Klinghoffer","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib32","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1128\/MCB.24.12.5340-5352.2004","article-title":"SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway","volume":"24","author":"Kontaridis","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1242\/jcs.114.11.2187","article-title":"SHP-2 complex formation with the SHP-2 substrate-1 during C2C12 myogenesis","volume":"114","author":"Kontaridis","year":"2001","journal-title":"J Cell Sci"},{"key":"10.1016\/j.tcm.2012.03.006_bib34","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","article-title":"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects","volume":"281","author":"Kontaridis","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/CIRCULATIONAHA.107.728865","article-title":"Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase\/mitogen-activated protein kinase and RhoA signaling pathways","volume":"117","author":"Kontaridis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2012.03.006_bib36","doi-asserted-by":"crossref","first-page":"18930","DOI":"10.1073\/pnas.0806556105","article-title":"Role of ERK1\/2 signaling in congenital valve malformations in Noonan syndrome","volume":"105","author":"Krenz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tcm.2012.03.006_bib37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jmg.39.8.571","article-title":"PTPN11 mutations in LEOPARD syndrome","volume":"39","author":"Legius","year":"2002","journal-title":"J Med Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/MCB.14.1.509","article-title":"A new function for a phosphotyrosine phosphatase: Linking GRB2-Sos to a receptor tyrosine kinase","volume":"14","author":"Li","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.amjcard.2007.03.093","article-title":"Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome","volume":"100","author":"Limongelli","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI44972","article-title":"Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation","volume":"121","author":"Marin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2012.03.006_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-3476(99)70088-0","article-title":"Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal","volume":"135","author":"Marino","year":"1999","journal-title":"J Pediatr"},{"key":"10.1016\/j.tcm.2012.03.006_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajhg.2010.06.015","article-title":"Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype","volume":"87","author":"Martinelli","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib43","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI30756","article-title":"Mediating ERK 1\/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome","volume":"117","author":"Nakamura","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2012.03.006_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp\u2019ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.tcm.2012.03.006_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0008-6363(02)00664-8","article-title":"Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts","volume":"57","author":"Ng","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2012.03.006_bib46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ng1749","article-title":"Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome","volume":"38","author":"Niihori","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib47","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1128\/MCB.14.10.6674","article-title":"Role of SH-PTP2, a protein-tyrosine phosphatase with src homology 2 domains, in insulin-stimulated ras activation","volume":"14","author":"Noguchi","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archpedi.1968.02100020377005","article-title":"Hypertelorism with Turner phenotype: A new syndrome with associated congenital heart disease","volume":"116","author":"Noonan","year":"1968","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.tcm.2012.03.006_bib49","first-page":"48","article-title":"The Ullrich-Noonan syndrome (Turner phenotype)","volume":"127","author":"Nora","year":"1974","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.tcm.2012.03.006_bib50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/hmg\/ddn336","article-title":"Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development","volume":"18","author":"Oishi","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib51","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ng2073","article-title":"Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy","volume":"39","author":"Pandit","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib52","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ng2078","article-title":"Germline gain-of-function mutations in RAF1 cause Noonan syndrome","volume":"39","author":"Razzaque","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1926","article-title":"Germline gain-of-function mutations in SOS1 cause Noonan syndrome","volume":"39","author":"Roberts","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib54","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/01.RES.77.6.1040","article-title":"Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy","volume":"77","author":"Sadoshima","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2012.03.006_bib55","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1136\/jmg.2003.013466","article-title":"Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome","volume":"41","author":"Sarkozy","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib56","doi-asserted-by":"crossref","first-page":"H231","DOI":"10.1152\/ajpheart.00665.2011","article-title":"The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling","volume":"302","author":"Schramm","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng1748","article-title":"Germline KRAS mutations cause Noonan syndrome","volume":"38","author":"Schubbert","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-8-13","article-title":"Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study","volume":"8","author":"Serra","year":"2007","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.tcm.2012.03.006_bib59","doi-asserted-by":"crossref","first-page":"13842","DOI":"10.1074\/jbc.M801510200","article-title":"Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function","volume":"283","author":"Shen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib60","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.110.977066","article-title":"Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice","volume":"123","author":"Shende","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2012.03.006_bib61","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1128\/MCB.20.5.1526-1536.2000","article-title":"Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity","volume":"20","author":"Shi","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib62","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000057979.36322.88","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice","volume":"107","author":"Shioi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2012.03.006_bib63","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1161\/HYPERTENSIONAHA.109.138818","article-title":"Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats","volume":"54","author":"Soesanto","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.tcm.2012.03.006_bib64","doi-asserted-by":"crossref","first-page":"C1256","DOI":"10.1152\/ajpcell.00338.2010","article-title":"mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy","volume":"299","author":"Song","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib65","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.devcel.2010.03.009","article-title":"Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis","volume":"18","author":"Stewart","year":"2010","journal-title":"Dev Cell"},{"key":"10.1016\/j.tcm.2012.03.006_bib66","doi-asserted-by":"crossref","first-page":"e1325","DOI":"10.1542\/peds.2006-0211","article-title":"The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene","volume":"119","author":"Sznajer","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.tcm.2012.03.006_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.genom.6.080604.162305","article-title":"Noonan syndrome and related disorders: Genetics and pathogenesis","volume":"6","author":"Tartaglia","year":"2005","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib68","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/340847","article-title":"PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity","volume":"70","author":"Tartaglia","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/499925","article-title":"Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease","volume":"78","author":"Tartaglia","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib70","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng1939","article-title":"Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome","volume":"39","author":"Tartaglia","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib72","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: Developmental syndromes of Ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.tcm.2012.03.006_bib73","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0955-0674(00)00196-4","article-title":"Combinatorial control of the specificity of protein tyrosine phosphatases","volume":"13","author":"Tonks","year":"2001","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib74","first-page":"1589","article-title":"Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584","volume":"7","author":"Vogel","year":"1996","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.tcm.2012.03.006_bib75","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/01.RES.0000041029.97988.E9","article-title":"Ras\/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes","volume":"91","author":"Wang","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2012.03.006_bib76","doi-asserted-by":"crossref","first-page":"H1056","DOI":"10.1152\/ajpheart.2000.278.4.H1056","article-title":"Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps","volume":"278","author":"Wang","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib77","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1074\/jbc.273.10.5423","article-title":"Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells","volume":"273","author":"Wang","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2012.03.006_bib78","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/HCO.0b013e3280f629c7","article-title":"The genetics of congenital heart disease: A review of recent developments","volume":"22","author":"Weismann","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.tcm.2012.03.006_bib79","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/hmg\/6.10.1647","article-title":"Craniosynostosis: Genes and mechanisms","volume":"6","author":"Wilkie","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.tcm.2012.03.006_bib80","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2012.03.006_bib81","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1073\/pnas.92.3.664","article-title":"Protein-tyrosine-phosphatase SHPTP2 is a required positive effector for insulin downstream signaling","volume":"92","author":"Yamauchi","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tcm.2012.03.006_bib82","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1210\/jc.2003-032091","article-title":"Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome","volume":"89","author":"Yoshida","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tcm.2012.03.006_bib83","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1172\/JCI43008","article-title":"MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice","volume":"120","author":"Zhang","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tcm.2012.03.006_bib84","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1128\/MCB.22.12.4062-4072.2002","article-title":"Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2","volume":"22","author":"Zhang","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.tcm.2012.03.006_bib85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1097-2765(04)00050-4","article-title":"Shp2 regulates SRC family kinase activity and Ras\/Erk activation by controlling Csk recruitment","volume":"13","author":"Zhang","year":"2004","journal-title":"Mol Cell"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173812000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173812000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T13:45:27Z","timestamp":1642340727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173812000436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1050173812000436"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2012.03.006","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}